Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…
Demand for Arthritis Care in America Outstrips Supply of Practicing Rheumatologists
May is National Arthritis Awareness Month. The ACR is committed to ensuring that arthritis and rheumatologic diseases are at the forefront of public awareness—and that better, safer treatments reach Americans in need. Fortunately, the federal government is also doing its part and has just released a major report on the national impact of arthritis. A…
How Tuberculosis Has Shaped Medicine and Society
Pathologists are legendary for blending their work product with the culinary arts. Through the years, their use of delectable foods as descriptors has created a clever way to indelibly link in the minds of clinicians the histopathologic observations of disease with an assortment of these tasty foods: There is the depiction of an apple green…
The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…
Rheumatology Case Report: Immune-Related Aortitis Associated with Ipilimumab
Ipilimumab (Yervoy) is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It was the first drug to demonstrate a survival benefit in advanced melanoma and was approved by the FDA in 2011.1 By blocking the CTLA-4 receptor, ipilimumab enhances the immune response against tumors via cytotoxic T lymphocyte activation and proliferation.2 However, immunopotentiating…
Four-Week Methotrexate Break Improves Flu Shot Response in RA Patients
NEW YORK (Reuters Health)—Temporarily withholding methotrexate (MTX) can improve the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA), according to a new randomized clinical trial. Response was strongest in patients who discontinued MTX for two weeks before and two weeks after receiving the flu shot, Dr. Eun Bong Lee of Seoul National…
Active Advocacy in the Sunshine State: Florida Society Presses for Legislative Changes to Protect Patient Access to Medications
At their state capitol in Tallahassee on March 28, seven board members of the Florida Society of Rheumatology (FSR) lobbied to support legislation regarding prior authorization, step therapy and non-medical switching. They also educated lawmakers about rheumatic diseases and how access to the right therapy may dramatically improve patients’ lives. “We talked about the problems encountered…
Alliance Working to Rein in Power of PBMs
A coalition of patient and provider groups, including the ACR, is raising awareness about the effect of pharmacy benefit managers (PBMs) on patient care and the cost of prescription drugs. The Alliance for Transparent and Affordable Prescriptions, or ATAP, argues that too few restrictions have been placed on PBM transparency, and requirements for PBMs to…
Advocating for CMMI Reform, Looking Ahead to Alternative Payment Models
The work of health policy reform is a marathon, not a sprint. The ACR is encouraged by the forward progress being made in collaboration with the American Medical Association and other physician-led organizations within the Healthcare Leaders for Accountable Innovation in Medicare and Medicaid coalition (known as the AIM coalition) to advocate for physicians’ ability…
Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis
Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…
- « Previous Page
- 1
- …
- 387
- 388
- 389
- 390
- 391
- …
- 776
- Next Page »